Exhibit 99.1

 

CLYWEDOG THERAPEUTICS, INC.

Condensed Consolidated Financial Statements

As of June 30, 2026 and December 31, 2025 and for

the Three and Six Months Ended June 30, 2026 and 2025

 

 

 

 

TABLE OF CONTENTS

 

Condensed Consolidated Financial Statements  
Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 F-3
Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2026 and 2025 F-4
Unaudited Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit for the Three and Six Months Ended June 30, 2026 and 2025 F-5
Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025 F-6
Notes to Unaudited Condensed Consolidated Financial Statements F-7

 

 

 

 

CLYWEDOG THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

 

   June 30,
2026
(Unaudited)
   December 31,
2025
 
Assets          
Current assets:          
Cash  $68,997   $220,196 
Prepaid research and development – related party   2,118,327    1,082,913 
Prepaid expenses and other current assets   74,178    1,990,915 
Total current assets   2,261,502    3,294,024 
Prepaid research and development - related party, non-current   145,700    - 
Prepaid research and development, non-current   511,690    725,781 
Total assets  $2,918,892   $4,019,805 
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Deficit          
Current liabilities:          
Accounts payable - related parties  $10,908,600   $- 
Accounts payable   4,278,429    912,421 
Accrued research and development – related parties   453,265    4,234,244 
Accrued expenses and other current liabilities   1,352,806    328,723 
Notes payable - related parties   1,539,985    - 
Total current liabilities   18,533,085    5,475,388 
Notes payable - related parties, non-current   -    1,476,417 
SAFE liabilities - related parties, non-current   20,663,000    20,349,000 
Total liabilities   39,196,085    27,300,805 
           
Commitments and contingencies (Note 5)          
           
Redeemable convertible preferred stock, $0.0001 par value:
6,476,164 shares authorized, issued, and outstanding. Aggregate liquidation preference of $13,509,997
   12,774,386    12,774,386 
           
Stockholders' Deficit          
Common stock: $0.0001 par value; 16,476,164 shares authorized; 1,512,000 shares issued and outstanding   151    151 
Additional paid-in capital   -    - 
Accumulated deficit   (49,051,730)   (36,055,537)
Total stockholders' deficit   (49,051,579)   (36,055,386)
Total liabilities, redeemable convertible preferred stock, and stockholders' deficit  $2,918,892   $4,019,805 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

F-3

 

 

CLYWEDOG THERAPEUTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2026   2025   2026   2025 
Operating expenses:                    
Research and development – related parties  $2,512,270   $547,780   $5,686,407   $4,376,260 
Research and development   2,475,779    1,929,743    6,059,768    1,937,628 
General and administrative   424,830    124,365    872,450    145,150 
Total operating expenses   5,412,879    2,601,888    12,618,625    6,459,038 
Loss from operations   (5,412,879)   (2,601,888)   (12,618,625)   (6,459,038)
                     
Other income (expense):                    
Loss on change in fair value of SAFE instruments - related parties   (217,000)   (729,000)   (314,000)   (1,683,000)
Interest expense - related parties   (31,972)   (30,163)   (63,568)   (69,966)
Gain on extinguishment of debt - related party   -    -    -    1,365,381 
Total other income (expense), net   (248,972)   (759,163)   (377,568)   (387,585)
Net loss  $(5,661,851)  $(3,361,051)  $(12,996,193)  $(6,846,623)
                     
Net loss per share attributable to common stockholders, basic and diluted  $(3.74)  $(2.22)  $(8.60)  $(4.53)
Weighted-average shares of common stock outstanding, basic and diluted   1,512,000    1,512,000    1,512,000    1,512,000 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

CLYWEDOG THERAPEUTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT

 

   Redeemable Convertible       Additional       Total 
   Preferred Stock   Common Stock   Paid-In   Accumulated   Stockholders' 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance as of December 31, 2025   6,476,164   $12,774,386    1,512,000   $151   $-   $(36,055,537)  $(36,055,386)
Net loss   -    -    -    -    -    (7,334,342)   (7,334,342)
Balance as of March 31, 2026 (unaudited)   6,476,164    12,774,386    1,512,000    151    -    (43,389,879)   (43,389,728)
Net loss   -    -    -    -    -    (5,661,851)   (5,661,851)
Balance as of June 30, 2026 (unaudited)   6,476,164   $12,774,386    1,512,000   $151   $-   $(49,051,730)  $(49,051,579)
                                    
Balance as of December 31, 2024   6,476,164   $12,774,386    1,512,000   $151   $-   $(19,050,315)  $(19,050,164)
Net loss   -    -    -    -    -    (3,485,572)   (3,485,572)
Balance as of March 31, 2025 (unaudited)   6,476,164    12,774,386    1,512,000    151    -    (22,535,887)   (22,535,736)
Net loss   -    -    -    -    -    (3,361,051)   (3,361,051)
Balance as of June 30, 2025 (unaudited)   6,476,164   $12,774,386    1,512,000   $151   $-   $(25,896,938)  $(25,896,787)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-5

 

 

CLYWEDOG THERAPEUTICS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   Six Months Ended
June 30,
 
   2026   2025 
Cash flows from operating activities:          
Net loss  $(12,996,193)  $(6,846,623)
Adjustments to reconcile net loss to net cash used in operating activities:          
Gain on extinguishment of debt - related party   -    (1,365,381)
Interest expense - related parties   63,568    69,966 
Loss on change in fair value of SAFE instruments - related parties   314,000    1,683,000 
Changes in operating assets and liabilities:          
Prepaid research and development - related party   (1,035,414)   4,697,815 
Prepaid research and development - related party, non-current   (145,700)   - 
Prepaid expenses and other current assets   1,916,737    (858,204)
Prepaid research and development, non-current   214,091    - 
Accounts payable - related parties   10,908,600    - 
Accounts payable   3,366,008    14,235 
Accrued research and development - related parties   (3,780,979)   1,534,853 
Accrued expenses and other current liabilities   1,024,083    (34,803)
Net cash used in operating activities   (151,199)   (1,105,142)
           
Net decrease in cash   (151,199)   (1,105,142)
Cash, beginning of period   220,196    2,789,483 
Cash, end of period  $68,997   $1,684,341 
           
Supplemental disclosure of non-cash investing and financing activities:          
Interest accrued on notes payable - related parties  $63,568   $69,966 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-6

 

 

CLYWEDOG THERAPEUTICS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. Organization and Description of Business

 

Clywedog Therapeutics, Inc. (the "Company") is a biopharmaceutical company involved in the discovery and development of small molecule modulators that target essential signaling pathways involved in development of major metabolic disease, such as Type 1 Diabetes, Type 2 Diabetes, and systemic lupus erythematosus, with the goal of prevention or reversal of such diseases. The Company was incorporated as Vyrnwy Therapeutics Inc. on December 17, 2020, pursuant to the laws of the State of Delaware. The Company subsequently changed its name to Clywedog Therapeutics, Inc. on October 10, 2024. The Company's headquarters are in Dover, Delaware.

 

Development-Stage Risks and Liquidity

 

The Company has a limited operating history and has incurred recurring losses and negative operating cash flows since inception. As of June 30, 2026, the Company had an accumulated deficit of $49.1 million and cash of $0.1 million. The Company has been primarily performing research and development activities, establishing and maintaining its intellectual property, and raising capital to support and expand its operations. To date, the Company has funded its operations primarily through the sale of its series seed redeemable convertible preferred stock and the issuance of Simple Agreements for Future Equity ("SAFEs" or "SAFE instruments"). The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. No assurance can be given that any such financing will be available when needed or that the Company's research and development efforts will be successful. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. The Company's condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern, which assumes the continuity of operations, the realization of assets and the settlement of liabilities and commitments as they come due in the normal course of business.

 

Achieving profitability is dependent upon the successful development, approval and commercialization of the Company's product candidate and achieving a level of revenues adequate to support the Company's expense structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital. Management's plans to address these conditions include completion of the pending Merger with Barinthus Bio described in Note 6 and, prior to the consummation of the Merger, raising additional capital through the issuance of one or more SAFE instruments, in an amount to be determined based on factors including the Company's projected cash runway requirements through the expected closing date of the Merger and the minimum net cash closing condition set forth in the Merger Agreement, as amended. Management's plans are not within the Company's control, including because the Merger is subject to conditions to closing and any SAFE issuance is subject to reaching agreement with investors, and therefore cannot be considered probable of being effectively implemented. As a result, management's plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern. The sale of equity or other securities may result in dilution to the Company's stockholders and certain of those securities may have rights senior to those of the Company's existing capital stock. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress the Company makes on its discovery and development efforts. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company's planned operations. The Company's future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company's current and potential future product candidates, uncertainty of market acceptance of the Company's product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers.

 

The Company's product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.

 

F-7

 

 

Global Uncertainties

 

In February 2022, the Russian Federation commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation. These sanctions may directly or indirectly affect the Company's ability to license, transfer, or otherwise commercialize its assets in Russia, discussed further in Note 9, and may limit the Company's ability to receive payments, enforce contractual rights, or protect its intellectual property in the region. The specific impact of this conflict and related sanctions on the Company's financial condition, results of operations, and cash flows is also not determinable as of the date of these condensed consolidated financial statements.

 

2. Significant Accounting Policies and Basis of Presentation

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information. Certain information and footnotes normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") promulgated by the Financial Accounting Standards Board ("FASB").

 

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Clywedog AU Pty Ltd, which was formed in December 2024 and had no operations during the three and six months ended June 30, 2026 and 2025 and the year ended December 31, 2025. All intercompany accounts and transactions have been eliminated in consolidation.

 

Unaudited Interim Financial Information

 

The accompanying interim condensed consolidated balance sheet as of June 30, 2026, the interim condensed consolidated statements of operations for the three and six months ended June 30, 2026 and 2025, the interim condensed consolidated statements of redeemable convertible preferred stock and stockholders' deficit for the three and six months ended June 30, 2026 and 2025, and the interim condensed consolidated statements of cash flows for the six months ended June 30, 2026 and 2025 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company's financial position as of June 30, 2026, the results of its operations for the three and six months ended June 30, 2026 and 2025, and the results of its cash flows for the six months ended June 30, 2026 and 2025. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2026 and 2025 are unaudited. The results for the three and six months ended June 30, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026, or any other interim periods, or any future year or period.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. The most significant estimates relate to the accrual of research and development expenses and valuation of the Company's SAFE liabilities.

 

F-8

 

 

Cash

 

Cash is comprised of cash deposits held with financial institutions.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Substantially all of the Company's cash deposits are maintained at one financial institution domiciled in the United States. Amounts on deposit with this financial institution may, from time to time, exceed the federally insured limit. The Company is exposed to credit risk in the event of default by the financial institution holding its cash to the extent recorded in the condensed consolidated balance sheets. The Company has not experienced any losses on its deposits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.

 

Research and Development Expenses

 

Research and development expenses consist primarily of cost of subcontractors and materials used for research and development activities, including preclinical studies, materials and supplies, and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, is included in research and development expenses and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the project and the invoices received from its external service providers. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable to be achieved.

 

Asset Acquisitions

 

Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions, with a cost accumulation model used to determine the cost of the acquisition. Common stock issued as consideration in an acquisition of assets is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of an acquisition of assets. Intangible assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in-process research and development ("IPR&D"). Acquired IPR&D that has no alternative future use is expensed immediately in the condensed consolidated statements of operations. See Note 9 for further information.

 

Fair Value Measurements

 

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

 

•Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

 

•Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

 

•Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

 

There were no transfers between Levels 1, 2, and 3 of such instruments during the periods presented. The carrying amounts of the Company's cash, prepaid expenses, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term nature. See Note 4 for further information.

 

F-9

 

 

Income Taxes

 

The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. As of June 30, 2026 and December 31, 2025, management believes it is more likely than not that no benefits will be derived from the Company's deferred tax assets.

 

The Company recognizes an uncertain tax position in its condensed consolidated financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. As of June 30, 2026 and December 31, 2025, the Company has not recorded any uncertain tax positions.

 

The tax years from 2021 and forward are subject to examination by federal tax and state tax authorities. In addition, tax years with net operating loss carryforwards are subject to examination, three years following the year they are utilized. The Company has not been informed by any tax authorities for any jurisdiction that any of its tax years is under examination.

 

SAFE Liabilities

 

The SAFE instruments issued in October 2024, December 2024, and November 2025 have the potential for cash settlement upon the occurrence of certain "liquidity events" (including a change of control, direct listing, or initial public offering) and "dissolution events" (including voluntary termination of operations, a general assignment for the benefit of the Company's creditors, or any other liquidation, dissolution or winding up of the Company (excluding a liquidity event), whether voluntary or involuntary). The instruments, at the election of the holder, can also be settled in shares of the Company's common stock, which are contingently redeemable upon a liquidation event that may obligate the Company to transfer assets at some point in the future. The SAFE instruments were determined to be liability classified at issuance and recorded at estimated fair value. The SAFE instruments are subject to remeasurement at each reporting date with changes in estimated fair value recognized in other income (expense) in the unaudited condensed consolidated statements of operations until settlement or termination in cash or shares. Refer to Note 4 for additional information.

 

Redeemable Convertible Preferred Stock

 

The Company records shares of its redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company classifies its preferred stock outside of total stockholders' deficit because, in the event of certain "liquidation events" (including a merger, acquisition or sale of all or substantially all of the Company's assets) that are not solely within the control of the Company, the shares would become redeemable at the option of the holders. The Company does not accrete the carrying values of the preferred stock to the redemption values since a liquidation event was not considered probable as of June 30, 2026 and December 31, 2025. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such a liquidation event will occur.

 

F-10

 

 

Net Loss Per Share Attributable to Common Stockholders

 

Net loss per share attributable to common stockholders is computed using the two-class method required for participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The Company's participating securities include the Company's redeemable convertible preferred stock. The holders of redeemable convertible preferred stock do not have a contractual obligation to share in losses of the Company, and, therefore, the net loss was attributed entirely to common stockholders for all periods presented.

 

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

 

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share attributable to common stockholders, because including them would have had an anti-dilutive effect.

 

   Three and Six Months Ended
June 30,
 
   2026   2025 
Redeemable convertible preferred stock   6,476,164    6,476,164 
SAFEs   2,086,301    687,616 
Total   8,562,465    7,163,780 

 

The number of shares issuable upon conversion of the SAFEs is not determinable until the occurrence of a qualified financing or other triggering event. Accordingly, the amounts presented represent management's estimate of the common stock equivalents during the periods presented.

 

Segments

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company's chief operating decision maker ("CODM") is the executive team, which includes the Chief Executive Officer and Chairman and the President and Chief Operating Officer. The Company's CODM manages the Company's operations on a consolidated basis for the purpose of allocating resources. The CODM assesses performance for its segment based on net loss, which is reported on the condensed consolidated statements of operations. The CODM uses net loss to evaluate the Company's overall financial performance, monitor the rate of cash consumption, and inform decisions regarding the allocation of resources across the Company's operations, including investment in research and development programs. The CODM is regularly provided with the Company's consolidated financial information. All significant segment expense categories and amounts, as well as other segment items, are identical to those presented on the face of the condensed consolidated statements of operations. The measure of segment assets is reported on the condensed consolidated balance sheet as total assets.

 

F-11

 

 

Forward Stock Split

 

On September 29, 2025, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a 7.56-for-1 forward stock split (the "stock split") of the Company's issued and outstanding shares of common stock. As a result of the stock split, each share of common stock issued and outstanding was converted into 7.56 shares of common stock. No fractional shares were issued in connection with the stock split. All common share and per share amounts presented in the financial statements and accompanying notes have been retroactively adjusted to reflect the stock split. The stock split applied to the Company's common stock only and did not affect the Company's redeemable convertible preferred stock, including the 6,476,164 preferred shares issued and outstanding and the original issue price of $2.086111 per share. In connection with the stock split, the holders of the redeemable convertible preferred stock waived any adjustment to the conversion price of the preferred stock resulting from the stock split, and each share of redeemable convertible preferred stock continues to be convertible into one share of common stock.

 

Recently Adopted Accounting Pronouncements

 

In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“ASU 2025-03”), to improve the requirements for identifying the accounting acquirer in Topic 805, Business Combinations. The amendments in ASU 2025-03 revise current guidance for determining the accounting acquirer for a transaction effected primarily by exchanging equity interests in which the legal acquiree is a variable interest entity that meets the definition of a business. The amendments require that an entity consider the same factors that are currently required for determining which entity is the accounting acquirer in other acquisition transactions. Entities will be required to apply the new guidance prospectively to any acquisition transaction that occurs after the initial application date. Adoption of this guidance is effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods with early adoption permitted. The Company elected to early adopt ASU 2025-03 as of July 1, 2025. The adoption did not have a material impact on the consolidated financial statements.

 

Recently Issued Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the condensed consolidated statements of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the condensed consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its condensed consolidated financial statement disclosures.

 

3. Balance Sheet Components

 

Prepaid Expenses and Other Current Assets

 

   June 30,
2026
   December 31,
2025
 
Prepaid research and development  $63,064   $1,951,062 
Prepaid insurance   11,114    39,853 
Total prepaid expenses and other current assets  $74,178   $1,990,915 

 

F-12

 

 

Accrued Expenses and Other Current Liabilities

 

   June 30,
2026
   December 31,
2025
 
Professional service fees  $218,791   $322,823 
Research and development   1,128,115    - 
Other general and administrative   5,900    5,900 
Total accrued expenses and other current liabilities  $1,352,806   $328,723 

 

4. Fair Value Measurements

 

SAFE liabilities - Related Parties

 

The Company's SAFE liabilities are Level 3 financial instruments measured at fair value on a recurring basis. The following table provides a summary of the changes in the estimated fair value of the SAFE liabilities:

 

   For the Six Months Ended 
   June 30, 
   2026   2025 
Balance as of December 31, 2025 and 2024  $20,349,000   $10,944,000 
Change in fair value of SAFE liabilities - related parties   314,000    1,683,000 
Balance as of June 30, 2026 and 2025  $20,663,000   $12,627,000 

 

The fair value of the SAFE liabilities were estimated using a probability-weighted expected return method using the following inputs:

 

   June 30,   December 31, 
   2026   2025 
Stock price   $12.66 - $13.32    $12.41 - $13.06 
Volatility   103.0% - 118.5%    103.5% - 122.0% 
Discount rate   22.1%    20.7% 
Expected term to event (in years)   0.25 - 0.75    0.08 - 0.75 
Probability of equity financing   2.5%    5.0% 
Probability of APO transaction   95.0%    90.0% 
Probability of liquidity event   1.25%    2.50% 
Probability of dissolution event   1.25%    2.50% 

 

5. Commitments and Contingencies

 

Guarantees and Indemnification

 

In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of the status or service as directors or officers. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of June 30, 2026, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.

 

F-13

 

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. As of June 30, 2026, there were no claims or proceedings pending against the Company.

 

6. Merger Agreement

 

On September 29, 2025, the Company, Barinthus Biotherapeutics plc ("Barinthus Bio"), a public limited company organized under the laws of England and Wales, Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc.) ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of Barinthus Bio, and Cdog Merger Sub, Inc. ("Merger Sub"), a Delaware corporation and a direct wholly owned subsidiary of Topco, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Topco in accordance with the Delaware General Corporation Law (the "Merger"). In connection with the Merger, Topco intends to change its corporate name to "Clywedog Therapeutics Holdings, Inc."

 

At the effective time of the Merger (the "Merger Effective Time"), subject to adjustment in accordance with the terms of the Merger Agreement, each share of common stock, $0.0001 par value per share, of the Company and each share of Series Seed Preferred Stock, $0.0001 par value per share, of the Company (collectively, the "Company Capital Stock"), other than Company Capital Stock held as treasury stock or owned by Topco or Merger Sub immediately prior to the Merger Effective Time, will be converted solely into the right to receive (i) a number of shares of Topco Common Stock determined by the Merger Exchange Ratio plus (ii) cash in lieu of any fractional shares, rounded down to the nearest whole share.

 

Amendment to the Merger Agreement

 

On February 22, 2026, the Company, Barinthus Bio, Topco, and Merger Sub entered into an Amendment to the Merger Agreement (the "Amendment"), which modified certain terms of the Merger Agreement. The Amendment replaced the previously fixed Merger Exchange Ratio of 4.358932 shares of Topco Common Stock per share of Company Capital Stock with a variable Merger Exchange Ratio within a range of 0.000305 to 0.000508, to be finally determined by the Company and Barinthus Bio in accordance with the Merger Agreement. The Merger Exchange Ratio was amended correspondingly with the amendment of the Scheme Exchange Ratio applicable to Barinthus Bio shareholders under the scheme of arrangement, which was revised to a number between 0.1 and 0.166667, as finally determined by the board of directors of Barinthus Bio, in order to maintain the agreed ownership split of Topco following the closing, under which former Barinthus Bio shareholders will own approximately 34% of Topco and the Company's stockholders will own approximately 66% of Topco on a fully diluted basis.

 

The Amendment also extended the minimum cash closing conditions for both the Company and Barinthus Bio. As amended, the Company is required to maintain minimum net cash of not less than $1,000,000 assuming the Closing occurs on May 31, 2026 or June 30, 2026. The minimum cash requirements for previously specified closing dates remained unchanged. All other terms and conditions of the Merger Agreement remain in full force and effect. The Closing is expected to occur in the second half of 2026.

 

7. Redeemable Convertible Preferred Stock

 

In January 2021, the Company issued an aggregate of 2,173,424 shares of its series seed redeemable convertible preferred stock ("preferred stock") at a purchase price of $2.086111 per share in exchange for net cash proceeds of approximately $4.5 million.

 

F-14

 

 

Pursuant to the terms of the Series Seed Preferred Stock Purchase Agreement (the "Agreement"), the Company was obligated to sell additional shares of its preferred stock to the same investors at a cash purchase price of $2.086111 per share in two subsequent closings upon achievement of certain milestones. The first closing specified the sale and issuance of 713,288 shares of preferred stock on the achievement of the Target 1 milestone (the "First Tranche Closing"). The second closing specified the sale and issuance of an additional 713,288 shares of preferred stock on the achievement of the Target 2 milestone (the "Second Tranche Closing"). The Company determined that its obligation to issue additional shares represent freestanding instruments, initially recorded at fair value, with fair value changes recorded in other income (expense) in the unaudited condensed consolidated statements of operations. In February 2022, the Company completed the First Tranche Closing and issued 713,288 shares of its preferred stock in exchange for gross cash proceeds of $1.5 million, thereby settling the First Tranche Closing tranche liability. In September 2022, the Company completed the Second Tranche Closing and issued 713,288 shares of its preferred stock in exchange for gross cash proceeds of $1.5 million, thereby settling the Second Tranche Closing tranche liability. Immediately prior to the closing of the First and Second Tranche Closings, the Company remeasured the respective tranche liability to its then fair value and the tranche liability balance was reclassified to convertible preferred stock.

 

In March 2024, the Agreement was amended to authorize the issuance of an additional 2,876,164 shares of its preferred stock at a purchase price of $2.086111 per share for gross cash proceeds of approximately $6.0 million.

 

Redeemable convertible preferred stock consisted of the following:

 

As of June 30, 2026 and December 31, 2025
Class  Shares
authorized
   Shares issued
and outstanding
   Aggregate
liquidation
preference
   Carrying
value
 
Series Seed   6,476,164    6,476,164   $13,509,997   $12,774,386 

 

The following are the key terms of the preferred stock:

 

Dividends

 

The holders of shares of preferred stock are entitled to receive dividends, out of any assets legally available, prior and in preference to any declaration or payment of any dividend on the common stock, payable only if and when declared. Such dividends are non-cumulative.

 

After payment of any such dividends on the preferred stock, any additional dividends or distributions shall be distributed among all holders of common stock and preferred stock in proportion to the number of shares of common stock that would be held by each such holder of all shares of preferred stock were converted to common stock at the then effective conversion rate. No dividends have been declared to date.

 

Optional Conversion

 

Each share of preferred stock is convertible at the option of the holder at any time after the issuance date of such share into such number of shares of common stock as is determined by dividing the applicable original issue price by the applicable conversion price for such series. The initial conversion price per share for each series of preferred stock shall be the original issue price of $2.086111 per share. Adjustments to the conversion price, if any, occur if additional shares of common stock have been issued at a price less than the respective preferred stock.

 

Automatic Conversion

 

Each share of preferred stock will automatically convert into shares of common stock at the conversion rate at the time in effect for such series of preferred stock immediately upon either of (1) the closing of the Company's sale of its common stock in an initial public offering pursuant to a registration statement on Form S-1 that results in at least $30.0 million of gross proceeds; or (2) the date, or the occurrence of an event, specified by vote or written consent or agreement of the holders of a majority of the then outstanding shares of preferred stock (voting together as a single class and not as separate series, and on an as-converted basis).

 

F-15

 

 

Liquidation Preference

 

In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of the preferred stock are entitled to receive out of the proceeds or assets of the Company available for distribution to its stockholders, prior and in preference to any distribution of the proceeds to the holders of common stock, a liquidation preference in the amount per share equal to the sum of the original issue price of $2.086111 per share, plus any declared but unpaid dividends on such share.

 

If the assets of the Company are insufficient to pay the holders of the preferred stock the full amount, the holders of the preferred stock will share pro rata in any distribution of the assets available for distribution.

 

If preferential amounts are paid in full, the remaining assets of the Company are distributed among the holders of the preferred stock and common stock pro rata based on the number of shares held by each shareholder.

 

Voting Rights

 

Each share of preferred stock has a number of votes equal to the number of shares of common stock into which it is convertible. Except as provided in the Company's amended or restated articles of incorporation, the holders of preferred stock and the holders of common stock vote together as one single class.

 

The holders of preferred stock are entitled to elect two directors of the Company. The holders of preferred stock and common stock (voting together as a single class and on an as converted basis) are entitled to elect the two remaining directors.

 

Redemption

 

The preferred stock is not currently redeemable; however, it is redeemable at the option of the holders in the event of certain "liquidation events" (including a merger, acquisition or sale of all or substantially all of the Company's assets) that are not solely within the control of the Company.

 

8. Stockholders' Deficit

 

The voting, dividend, and liquidation rights of the holders of the Company's common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock set forth above. Each share of common stock entitles the holder to one vote, together with the holders of the preferred stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company's board of directors, subject to the preferential dividend rights of redeemable convertible preferred stock. As of June 30, 2026 and December 31, 2025, the Company's certificate of incorporation, as amended and restated, authorized the Company to issue 16,476,164 shares of common stock with a par value of $0.0001 per share. As of June 30, 2026 and December 31, 2025, there are 1,512,000 shares of common stock issued and outstanding. The Company has 6,476,164 shares of common stock reserved for issuance upon the conversion of its outstanding redeemable convertible preferred stock as of June 30, 2026 and December 31, 2025. The Company has 2,086,301 and 1,100,186 shares reserved for issuance upon settlement of its outstanding SAFEs, as of June 30, 2026 and December 31, 2025, respectively.

 

2020 Stock Plan

 

On December 17, 2020, the Board of Directors of the Company approved the adoption of the 2020 Stock Plan (the "Plan") that provides for the issuance of stock options, restricted stock, and other equity awards to employees, directors, and consultants. Under the Plan as amended and restated, the Company is authorized to issue up to 1,512,000 shares of common stock. As of June 30, 2026, no awards have been granted under the Plan, and 1,512,000 shares remain available for issuance.

 

F-16

 

 

9. Related Party Transactions

 

Research and Development Arrangements with Related Parties

 

In January 2021, the Company entered into a Master Research and Development Agreement with ChemDiv, Inc. ("ChemDiv"), pursuant to which ChemDiv provides services related to preclinical drug discovery to the Company. Dr. Nikolay Savchuk, Chief Executive Officer ("CEO") of the Company, is a stockholder of ChemDiv and a member of its board of directors. During the three and six months ended June 30, 2026, $0.7 million and $1.5 million, respectively, were expensed as research and development cost in the unaudited condensed consolidated statements of operations related to ChemDiv services. During the three and six months ended June 30, 2025, $0.0 million and $0.4 million, respectively, were expensed as research and development cost in the unaudited condensed consolidated statements of operations related to ChemDiv services. The Company recorded $0.2 million and $1.1 million as prepaid research and development expense in the unaudited condensed consolidated balance sheets related to ChemDiv services as of June 30, 2026 and December 31, 2025, respectively, of which $0.1 million was classified as prepaid research and development - related party, non-current as of June 30, 2026. Accrued expenses of $0.5 million related to ChemDiv services were recorded in the unaudited condensed consolidated balance sheets as of June 30, 2026. Accounts payable of $0.4 million related to ChemDiv services were recorded in the unaudited condensed consolidated balance sheets as of June 30, 2026.

 

In September 2023, the Company entered into a Master Research and Development Agreement with Expert Systems, Inc. ("Expert Systems"), a pharmaceutical company involved in the research, development, manufacturing, and sale of pharmaceutical products. An immediate family member of Dr. Savchuk, the Company's CEO, had a direct interest in Expert Systems by virtue of his minority ownership in Expert Systems. Effective April 1, 2025, Dr. Savchuk's family member ceased his relationship with Expert Systems and Expert Systems is no longer a related party. During the six months ended June 30, 2025 and prior to termination of the related party relationship with Expert Systems, $2.5 million, was expensed as research and development cost in the unaudited condensed consolidated statements of operations related to Expert Systems services.

 

In January 2025, the Company entered into a Master Services Agreement with Eilean Therapeutics AU Pty Ltd ("Eilean AU"), a party related because it shares common significant investors, whereby Eilean AU will provide clinical research support services to the Company. During the three and six months ended June 30, 2026, $1.8 million and $4.2 million, respectively, were expensed as research and development cost in the unaudited condensed consolidated statements of operations related to Eilean AU services. During the three and six months ended June 30, 2025, $0.5 million and $1.5 million, respectively, were expensed as research and development cost in the unaudited condensed consolidated statements of operations related to Eilean AU services. As of June 30, 2026 and December 31, 2025, $2.0 million and $0.0 million, respectively, were recorded as prepaid research and development expense in the unaudited condensed consolidated balance sheets related to Eilean AU services. As of June 30, 2026 and December 31, 2025, $0.0 million and $4.2 million, respectively, were recorded as accrued research and development - related parties in the unaudited condensed consolidated balance sheets related to Eilean AU services. Accounts payable of $10.5 million related to Eilean AU services were recorded in the unaudited condensed consolidated balance sheets as of June 30, 2026, representing substantially all of the $10.9 million of accounts payable - related parties as of that date.

 

Related Party Licensing and Notes Payable

 

In February 2025, the Company entered into a licensing agreement with Viriom, Inc. ("Viriom"), whereby Viriom acquired exclusive rights in the Russian Federation to the TKY2 inhibitor (the "TKY2 Licensed Molecule") for the treatment of diabetes mellitus, juvenile diabetes, and psoriasis ("TKY2 Indications") as monotherapy or as co-administered in combination with small molecule drugs or biological drugs (the "TKY2 Viriom License Agreement"). Under the terms of the agreement, the Company has granted Viriom an exclusive license, with the right to grant and authorize sublicenses, under the Company's patents and know-how to develop, test, make and use of the TKY2 Licensed Molecule to develop, test, make, have made, use, sell, offer for sale, import and otherwise exploit the product as it relates to the TKY2 Indications during the term of the TKY2 Viriom License Agreement. As consideration for the TKY2 Viriom License Agreement, Viriom has agreed to pay the Company a percentage of net sales of certain products during certain royalty periods. To date, no payments have been made, and no income or expenses were recognized under the TKY2 License Agreement. Refer to "Global Uncertainties" under Note 1 for further information.

 

Entry into the TKY2 Viriom License Agreement constitutes a related party transaction as Dr. Savchuk, the Company's CEO, has investment control of Viriom and indirectly holds a significant number of its shares of common stock through a limited liability company of which Dr. Savchuk is the managing member and equity holder.

 

In December 2024, the Company entered into a license agreement with Bala Therapeutics, Inc. ("Bala") (the "Bala License Agreement"). Bala is a wholly-owned subsidiary of Eilean Therapeutics, LLC ("Eilean"), a party related though Dr. Iain Dukes, Chairman of the Company's board of directors. Dr. Dukes has served as the Chief Executive Officer and Chairman of Eilean since February 2020. Pursuant to the Bala License Agreement, the Company obtained exclusive, perpetual licensing rights for the development of the Balamenib ZE63-0302 compound from Bala.

 

F-17

 

 

In exchange for the license, the Company issued a promissory note to Bala of $1.4 million for payment of the license fee. The promissory note bears interest at a rate of 7% per annum, compounded annually, and matures in December 2026. The promissory note may be prepaid without penalty and provides for customary events of default. Because the license is an IPR&D asset with no alternative future use, the fair value of the promissory note issued as the license fee to Bala was recorded immediately as research and development cost in the Company's consolidated statement of operations for the year ended December 31, 2024. The promissory note was initially recorded at its estimated fair value, which was less than its face amount, resulting in a debt discount of approximately $46,500. The discount is amortized to interest expense over the term of the note, resulting in an effective interest rate of approximately 8.8% per annum. As of June 30, 2026 and December 31, 2025, the unamortized debt discount was approximately $11,800 and $23,300, respectively, and is presented as a direct deduction from the note balance within notes payable - related parties in the condensed consolidated balance sheets. Interest expense of approximately $32,000 and $63,600, including amortization of the debt discount, was recorded in the Company's condensed consolidated statements of operations relating to the promissory note with Bala during the three and six months ended June 30, 2026, respectively. Interest expense of approximately $30,200 and $60,000 was recorded during the three and six months ended June 30, 2025, respectively.

 

In December 2024, the Company also entered into a license agreement with Mwyngil Therapeutics, Inc. ("Mwyngil") (the "Mwyngil License Agreement"). On February 1, 2025, the Company and Mwyngil entered into a termination agreement, whereby the Company and Mwyngil mutually agreed to terminate the Mwyngil Licensing Agreement and the related promissory note payable to Mwyngil. Prior to the termination, the Company recorded interest expense of approximately $10,000 on the promissory note payable to Mwyngil during the six months ended June 30, 2025, which is included in interest expense - related parties in the unaudited condensed consolidated statements of operations. The Company recognized a gain on extinguishment of the promissory note of $1.4 million in the condensed consolidated statement of operations during the six months ended June 30, 2025.

 

Related Party SAFE Instruments

 

The Company has issued SAFEs to TPAV, LLC ("TPAV") and OrbiMed Private Investments VIII, LP ("OrbiMed"), each an existing investor in the Company's series seed redeemable convertible preferred stock. TPAV is a related party through Dr. Nikolay Savchuk, the Company's Chief Executive Officer, and OrbiMed is a related party through Dr. Iain Dukes, Chairman of the Company's board of directors. The Company issued SAFEs to the two investors in equal amounts at each of three closings, for aggregate purchase amounts of $5.0 million in October 2024, $5.0 million in December 2024 and $6.0 million in November 2025, in each case on identical terms. The instruments have no stated maturity date and bear no interest. They convert automatically into shares of capital stock upon a qualified equity financing, and into common stock of the issuer upon an APO transaction, being a merger, reverse merger, acquisition or other business combination involving the Company and a publicly traded or blank check company. As of June 30, 2026 and December 31, 2025, SAFE liabilities - related parties were $20.6 million and $20.3 million, respectively, and are carried at fair value as described in Notes 2 and 4. During the three and six months ended June 30, 2026, the Company recognized losses on the change in fair value of these instruments of $0.2 million and $0.3 million, respectively, in loss on change in fair value of SAFE instruments within other income (expense) in the unaudited condensed consolidated statements of operations. During the three and six months ended June 30, 2025, the Company recognized losses on the change in fair value of these instruments of $0.7 million and $1.7 million, respectively.

 

10. Subsequent Events

 

The Company has evaluated subsequent events through August 31, 2026, the date these condensed consolidated financial statements were available to be issued.

 

F-18